Profile

Pattern Pharma’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity by targeting TLR4, in order to address cancers and infectious diseases. PPI-100 activates innate immune cells, increasing antigen-presenting activities directed at tumor antigens and resulting in anti-cancer cytotoxic T-cells and long-term T-cell memory. Pattern's initial focus is on a large, white-space opportunity to address the >40% relapse rate in cancer patients 5 years after surgery. Pattern collaborates with MD Anderson, Harvard, McGill and the University of Toronto.


Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

42 in total